Market News

New pricing structure will see the removal of any upfront investment costs for pharmaceutical companies looking to access the CDMO’s serialisation capabilities.

Acquisition expected to double the Italian manufacturer's generics portfolio.

Changes aligned to the company's strategic roadmap 2020.

US guidelines now recommend Entresto as standard of care for HFrEF as an alternative to ACEs or ARBs.

Acquisitions comprise operations in the US, Sweden and India.

Doxycycline Hyclate DR Tablets are a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne.

Eurasian operations and production strategies examined at CPHI Russia and CPHI South East Asia.

The contract is to conduct in vivo studies of generic drug products in human subjects from 2016 through to 2021.

The delivery system is for Adept Pharma's Narcan - the first FDA-approved nasally administered, needle-free, ready-to use medication that can stop or reverse the effects of an opioid overdose.

Peel-ID greatly reduces the risk of human error resulting from the incorrect kit being pulled from inventory due to illegible handwriting or incorrectly transposed numbers.

Acquisition provides Alvotech with complimentary capabilities in biosimilar development.

HuScreen will initially focus on popular indications such as colorectal, gastric, lung (small and non-small cell type), ovarian and breast cancer.

Afucosylation can enable more precise assessment of allergic sensitization.

Reduction is part of the company's ongoing efforts to conserve cash as it works to complete the requirements for an NDA submission of Firdapse (amifampridine phosphate) for the treatment of Lambert-Eaton myasthenic syndrome and congenital myasthenic sy...

Launch of early access programme for Noyada, first novel oral liquid formulation of Captopril targeting paediatric cardiovascular conditions and type 1 diabetic nephropathy.

$280 million project increases workforce, adds new capabilities

Albumedix albumin-based half-life extension technology used in clinical development of Hebei Changshan Biochem Pharma’s once-weekly diabetes treatment for the Chinese market.

Paul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis.

The installation and validation of Becomix homogenizer mixer new equipment extends the company’s ability to manufacture creams, ointments, and semi-solids

Investors may want to keep a close eye on both of these companies as key FDA response dates approach and PDUFA and ANDA decisions could serve as key catalysts for the stock price.

The Business will bring Mylan a complementary portfolio of approximately 25 branded and generic topical products, an active pipeline of approximately 25 products, and an established US sales and marketing infrastructure targeting dermatologists.

Significant unmet needs within veterinary care are driving veterinarians to treat animals such as dogs, cats and horses by prescribing drugs intended for human use.

First preservative-free multi-dose eye drop featuring Aptar Pharma’s OSD in the US.

The Huntington’s disease pipeline will see exciting new developments over the next decade as disease-modifying drugs transform the market landscape,’ says GlobalData.

LZ Lifescience to partner with North Carolina State University’s Biomanufacturing Training and Education Center to help promote and support technology expertise in the biopharma industry.

Construction now complete on new 62,000 square foot facility.

Production of commercial-scale product scheduled for January 2017.

Leading CDMO claims prestigious customer award from one of the top-20 biopharmaceutical companies.

Representatives of AbbVie, Eli Lilly, NNE Pharmaplan, Roche Diagnostics and Vetter Pharma reported on unusual projects, current challenges and future trends, such as filling of highly potent pharmaceuticals and innovative approaches for the development...

The purpose of the joint venture is to produce Neovacs' Kinoid immunotherapy product candidates, including IFNa-Kinoid.

GE Healthcare delivers world’s first modular manufacturing solution based on single-use bioprocessing technology in just 18 months.

Rodolfo Savitzky appointed as new CFO for Lonza Group to succeed Toralf Haag who was appointed as CFO of the Voith Group in Germany

The technology is underway to replace HEK293 as current production host for adenoviral vectors.

Tufts CSDD Impact Report says drug developers will be under more pressure to provide harder evidence of clinical superiority and cost-effectiveness of their products

Expanding capabilities in formulation development to include specialist pre-formulation, formulation prototyping and formulation development services.

Zenith Technologies and Werum IT Solutions to help improve pharma companies' production performance.

Investment in a PSD-1 spray dryer will allow the company to scale-up the process to support later clinical phases and niche commercial scale.

Complements a fast growing complex product pipeline in the region.

The white paper reviews the present state of how the pharmaceutical industry maps its upstream raw material supply chain and the associated challenges that accompany it.

Company says it is committed to ensuring previous mistakes are not repeated.

The new suites are part of a £3 million investment, which has increased the company’s overall manufacturing capacity

Through this agreement, Sun Pharma commits development of Cissampelos pariera (Cipa), a botanical drug in collaboration with ICGEB.

Ritchie Mooney appointed as Sales Specialist, based in the Republic of Ireland.

Positions AMRI as one of the largest independent developers and suppliers of API to the pharmaceutical industry.

Larger Carlsbad, California facility will allow seamless scale-up customer support from clinical to commercial scales.

New event will cover full pharmaceutical value chain, bringing together key buyers and sellers of pharmaceutical ingredients, contract services, packaging, machinery/technology, finished dosage formulations and bio services within the North American ma...

4500 formulations across 60 dosage forms, with 700 APIs and 200 finished products for Western markets present at CPHI China.

Name change comes after receiving reports of name confusion in the marketplace between Brintellix and the anti-blood clotting therapy Brilinta (ticagrelor).

Biogen to focus on novel therapies for neurology.

The ruling confirms the Court's prior injunction against the manufacture or sale of the generic version of non-crush-resistant Opana ER.

Marina to pursue Phase III studies for use of intranasal ketamine in multiple indications.

Strong growth will be driven by a robust late-stage pipeline, including valuable targeted therapies such as dupilumab and ixekizumab, says GBI Research.

The proceeds will be used to further the development of GB-102, Graybug Vision’s lead drug for wet AMD, through Phase II clinical trials and to initiate a clinical program for the company’s proprietary glaucoma compound.

Flexible factory concept allows accelerated drug development and delivery to market.

Senior appointment made just weeks after the sterile manufacturing specialist unveiled a significant surge in demand for its services from the US, driven by biotechnology firms looking for small-scale aseptic manufacturing capabilities in the EU to sup...

First company to launch a generic version of Crestor to customers in the US.

200,000 sq ft state-of-the-art biopharmaceutical manufacturing facility supports expanding development pipeline and transition toward commercial stage.

New Lynx CDR connectors facilitate faster and more economic biopharma fluid management.

The system can be applied over a broad range of process conditions, including those containing temperature-sensitive active ingredients.

Combination would create complementary offerings to treat prostate cancer.

Although a number of key patent expiries will occur during the forecast period, new drugs will offset this and drive strong growth, says GBI Research.

The event will be tackling issues such as the rise of precision medicine, disruptive thinking in pharmaceutical regulation, improving patient compliance, future pharmaceutical supply chains and more.

Launching products at INTERPHEX 2016 include 1000-L bioreactor for greater flexibility and continuity for scale-up.

The commercial launch of the CAS is the first in a series of product launches that enable continuous bioprocessing.

There is a potential difference of hundreds of millions of dollars in sales at stake across therapy lines between the first-to-market product and the runner-up, says GlobalData

Also offers a powerful state-of-the-art refrigeration system with advanced temperature management.

OptiForm Solution Suite — designed to efficiently and rapidly help solve complex bioavailability challenges for early-stage molecules, using a unique toolkit of bioavailability enhancing technologies.

This new service offers a number of advantages compared with current analytical techniques.

D-series analysers are supplied with new 'in-die' and 'out-of-die' compaction analysis software that generates tablet detachment and ejection data with full profiles.

The rise will be small due to the government’s focus on reducing healthcare expenditure and the increasing popularity of generics, says GlobalData.

Visible particulate matter — glass — observed by the company of reserve samples.

The move comes in response to increasing demand for its products and services.

Brings more than three decades of leadership and operations experience in healthcare.

Provides manufacturing capabilities for more than 40 different product formulations.

Adds global rights to XAF5, potential first-in-class topical treatment for steatoblepharon, or undereye bags.

The expansions will help the company to meet the increasing worldwide demand for its diabetes medicines.

Facility needed to meet growing export demand for GSK respiratory medicines.

Technology aims to solve patient competence and adherence challenges, minimizing burden on health care providers and payers.

Only manufacturer to offer the antibiotic in a ready-to-use premixed presentation.

300 content sessions stimulating new ideas to propel Turkey towards a top-ten pharma economy.

Despite its strong position in the HIV space, Gilead will face significant competition from Janssen and ViiV, as potentially successful outcomes of clinical trials could shift market dynamics.

Patients who fill three or more chronic medications on a regular basis are eligible for the service and will enroll directly with their Rexall pharmacist. Following enrollment, in consultation with their pharmacist, a patient's medications will be sync...

Novel enzymatic, 1-step site-specific protein conjugation technology for ADC production.

The team has experience with developing polymeric materials for implantable medical devices, drug delivery technologies, therapeutics, excipients and medical-grade coatings.

The company signs two separate agreements to acquire Kemwell’s pharmaceutical contract development and manufacturing (CDMO) businesses.

Electronic components offer almost unlimited possibilities to display large, clear and legible counter digits required for a wide range of user age segments and medical conditions.

Acquisition enhances WuXi's structure-based drug discovery capabilities and establishes WuXi research facilities within Europe .

Help for owners of SMEs who are still unclear on how leaving or staying in the EU will affect their businesses.

Optimized performance and energy efficiency.

Companies are working together to drive product development of the Gamlen range of powder compaction analysers.

Emverm provides a new option for patients with pinworm, whipworm, roundworm and hookworm in single or mixed infections.

Webinars will discuss tablet design and tool material selection, tool features and configuration and tooling maintenance and lifecycle management.

Significantly bolsters presence in high growth developing territories and the deal firmly establishes Recipharm’s emerging market strategy.

Focus on Microbiological contamination control and risk in pharmaceuticals, cosmetics and toiletries.

Merck obtains CE mark certification for consumables of Gavi and Geri as well as for the embryo culture media suite Gems.

Kalorama thinks Pfizer will continue to spotlight its vaccine business.

New company to develop novel cell-based cancer immunotherapies in China.

Adds selective muscarinic agonists discovered and developed by Heptares to Allergan's leading CNS pipeline.

Sales in Middle East to grow significantly in next 2 years.

Agreements relate to Eisai's global oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as well as the company's global epilepsy therapy, Fycompa (perampanel).

The merged company will combine deep technical expertise in process development and clinical manufacturing.

Allergan reiterates strong standalone growth profile and strategy following termination of Pfizer transaction.

Growth due to increasing complexity around affiliates’ roles.

Global market trends, growth and forecast to 2020.

New tablet attaches to the lining of the GI tract, resists being pulled away.

The parties created IPS-MRCT Joint Centre for Therapeutic Antibodies to combine their expertise in research and development, intellectual property (IP) protection and management, and commercial acumen for more precise and efficient technology transfer.

In spite of similar approval numbers, the US continue to outpace Europe.

Rising prevalence of infectious diseases and cancer, significant nanotechnology research, and increasing demand for novel drug delivery systems are driving the nanotechnology market.

Purchase will expand Humanwell’s and PuraCap’s US Generics platform.

The combined offering is aimed at helping biopharmaceutical manufacturers increase productivity, improve efficiency and reduce costs.

ISO 8655:2002 recommends using pipettes and tips that are sourced from the same manufacturer.

Enabling direct substitution in commercial enteric pharmaceutical formulations.

Progeny 1064nm handheld Raman analyser fully compliant with EP 2.2.48 to support pharmaceutical manufacturers with rapid and reliable raw material identification.

Company receives EPA honor for 11th consecutive year.

Company recognized with ENERGY STAR Award for fifth time.

Strategic acquisition of 14 prescription brands.

BioChain to acquire exclusive development and commercial license for China.

The availability of commercial ready-to-assay cryopreserved cells in a qualified kit will remove the need for developers to employ challenging and time-consuming method development procedures.

Seventeen abstracts to be presented, including new analyses from the Phase III ARISTOTLE and AMPLIFY clinical studies and from real-world databases.